BioLife Solutions makes and sells specialty consumables used in cell and gene therapy (CGT) manufacturing. The core product is biopreservation media (BPM), which accounts for roughly 85% of revenue. BPM comes in two main forms: CryoStor freeze media, used to cryopreserve cells, and HypoThermosol FRS, used to preserve cells at cold but non-frozen temperatures during transport or handling. BioLife's formulations are engineered to minimize cell damage during cooling, freezing, and rewarming — a critical factor because cell viability directly affects the quality of the therapy being manufactured. Beyond BPM, BioLife sells complementary cell processing tools including CellSeal and CryoCase rigid containers for final-dose packaging, human platelet lysate media for cell expansion, CT-5 automated fill machines, and ThawSTAR automated thawing devices. BioLife sells to CGT developers ranging from clinical-stage biotechs to large pharma companies, primarily through a direct sales force. BioLife's business model is consumable-driven: the more doses a customer produces, the more BPM and related products they consume. Revenue scales with the number of approved therapies using BioLife products, dose volumes from those therapies, and cross-sell adoption of non-BPM tools. BioLife's BPM products are embedded in 16 approved therapies and used in over 250 commercially sponsored CGT clinical trials, representing roughly 80% share among Phase 3 trials. BioLife's growth strategy centers on riding CGT market growth as clinical programs advance to approval, cross-selling processing tools to existing BPM customers, and expanding its portfolio through targeted M&A.